Press Releases - Renalytix

Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report

10.27.20

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its full

RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update

10.16.20

Renalytix AI plc ("RenalytixAI" or the "Company") Notice of results Analyst and Investor presentations NEW YORK , Oct. 16, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management

RenalytixAI Receives California Commercial Laboratory Certification

09.22.20

RenalytixAI is now currently licensed to provide KidneyIntelX testing services for patients in 49 states NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Renalytix AI, Inc. (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical

RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System

09.18.20

NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the

RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX

08.26.20

NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it

RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease

08.21.20

Parties to adopt multi-phase approach to develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), today announced a collaboration with AstraZeneca

KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients

08.03.20

Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Mount Sinai Health System and Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), announce the initiation of a

RenalytixAI Announces Over Allotment Option Exercise Raises an Additional US$10.9M

07.27.20

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower

RenalytixAI Announces Closing of Global Offering and Resulting Total Voting Rights

07.21.20

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower

RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market

07.16.20

NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs,